Tseng Yen-Chiang, Tseng Yen-Han, Kao Hua-Lin, Hsieh Chih-Cheng, Chou Teh-Ying, Goan Yih-Gang, Hsu Wen-Hu, Hsu Han-Shui
Division of Thoracic Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Institute of Clinical Medicine, National Yang-Ming University, National Yang-Ming University School of Medicine, Taipei, Taiwan.
PLoS One. 2017 Jun 20;12(6):e0179527. doi: 10.1371/journal.pone.0179527. eCollection 2017.
Thymoma has a variable long-term oncological outcome after surgical resection. Survival and tumor recurrence were analyzed to determine the predisposing factors for tumor recurrence.
A total of 235 patients who underwent surgery for thymoma or thymic carcinoma from December 1997 to March 2013 were analyzed using Masaoka staging system and World Health Organization (WHO) histological classification. Surgical intervention included extended thymothymectomy via median sternotomy and thymomectomy via thoracotomy/ video-assisted thoracoscopic surgery (VATS).
The median duration of follow-up was 105 months (12-198 months). Among these 235 patients, recurrence was observed in 25 patients (10.7%). according to Masaoka stage I, IIA, IIB, III, IVA, IVB, recurrence rates were 1/65(1.5%), 8/106(7.5%), 1/32(3.1%), 6/20(30.0%), 8/10(80.0%), 1/1(100.0%), respectively. Disease or treatment-related mortality was observed in 13 patients. Overall survival rate was 94.4%. After univariate analysis, predisposing factors for tumor recurrence included Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.
Due to the indolent behavior of thymoma, tumor recurrence appears to be a better assessment of oncological outcome rather than survival. Factors associated with tumor recurrence include Masaoka stage, WHO histologic type, tumor size, adjuvant therapy and margin status.
胸腺瘤手术切除后的长期肿瘤学预后存在差异。分析生存率和肿瘤复发情况以确定肿瘤复发的易感因素。
采用Masaoka分期系统和世界卫生组织(WHO)组织学分类法,对1997年12月至2013年3月期间接受胸腺瘤或胸腺癌手术的235例患者进行分析。手术干预包括经正中胸骨切开术的扩大胸腺切除术和经开胸手术/电视辅助胸腔镜手术(VATS)的胸腺切除术。
中位随访时间为105个月(12 - 198个月)。在这235例患者中,25例(10.7%)出现复发。根据Masaoka分期I、IIA、IIB、III、IVA、IVB,复发率分别为1/65(1.5%)、8/106(7.5%)、1/32(3.1%)、6/20(30.0%)、8/10(80.0%)、1/1(100.0%)。观察到13例患者出现疾病或治疗相关死亡。总生存率为94.4%。单因素分析后,肿瘤复发的易感因素包括Masaoka分期、WHO组织学类型、肿瘤大小、辅助治疗和切缘状态。
由于胸腺瘤生长缓慢,肿瘤复发似乎比生存率更能评估肿瘤学预后。与肿瘤复发相关的因素包括Masaoka分期、WHO组织学类型、肿瘤大小、辅助治疗和切缘状态。